These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2126697)

  • 21. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate.
    Thorburn CE; Molesworth SJ; Sutherland R; Rittenhouse S
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2796-801. PubMed ID: 9124843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of an orally administered cephalosporin, LY164846, against potentially pathogenic respiratory and dermal bacterial isolates.
    Lauderdale BL; Yu PK; Washington JA
    Antimicrob Agents Chemother; 1986 Apr; 29(4):560-4. PubMed ID: 3486628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of the tricyclic beta-lactam GV104326.
    Wise R; Andrews JM; Brenwald N
    Antimicrob Agents Chemother; 1996 May; 40(5):1248-53. PubMed ID: 8723475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro activity and beta-lactamase stability of LY163892.
    Cao C; Chin NX; Neu HC
    J Antimicrob Chemother; 1988 Aug; 22(2):155-65. PubMed ID: 3263352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro activity of the new oral cephalosporin Bay v 3522 against aerobic and anaerobic bacteria.
    Rylander M; Nord CE; Norrby SR
    Eur J Clin Microbiol Infect Dis; 1990 Oct; 9(10):777-82. PubMed ID: 2261923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
    Bauernfeind A; Jungwirth R
    Infection; 1991; 19(5):353-62. PubMed ID: 1800377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
    Wise R; Andrews JM; Ashby JP; Thornber D
    Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.
    Sader HS; Johnson DM; Jones RN
    Antimicrob Agents Chemother; 2004 Jan; 48(1):53-62. PubMed ID: 14693518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
    Johnson DM; Biedenbach DJ; Beach ML; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.
    Clark C; McGhee P; Appelbaum PC; Kosowska-Shick K
    Antimicrob Agents Chemother; 2011 May; 55(5):2344-51. PubMed ID: 21343467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens.
    Dubois J; St-Pierre C
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):187-93. PubMed ID: 10904192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of respiratory tract pathogens in Finland to cefixime and nine other antimicrobial agents.
    Lehtonen L; Huovinen P
    Scand J Infect Dis; 1993; 25(3):373-8. PubMed ID: 8362234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of cefcanel versus other oral cephalosporins.
    Chin NX; Gu JW; Neu HC
    Eur J Clin Microbiol Infect Dis; 1991 Aug; 10(8):676-82. PubMed ID: 1748125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates.
    Murray PR; Allen SD; Erwin ME; Gerlach EH; Jones RN; Koontz FP; Pfaller MA; Washington JA
    Eur J Clin Microbiol Infect Dis; 1991 Sep; 10(9):776-81. PubMed ID: 1810737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
    Diagn Microbiol Infect Dis; 1986 Jul; 5(2):151-62. PubMed ID: 3522088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.